[Bisphosphonates for osteoporosis].
Narusawa
Ken'ichiro
K
Department of Orthopaedic Surgery, University of Occupational and Environmental Health, Japan.
Nakamura
Toshitaka
T
D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000075202:Contraindications; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D019317:Evidence-Based Medicine; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate